[Development trend in new therapeutic approaches for anemia].
For cancer treatment-related anemia, it is recommended to use erythropoietin or darbepoetin alpha by the National Comprehensive Cancer Network (NCCN). The guideline proposed the risk assessment for anemia, as well. The introduction of erythropoietin or darbepoetin alpha for anemia in treated cancer patients is based on the improvement of quality of life. For patients with myelodysplastic syndrome (MDS), those with 5q- anomaly is recommended to use lenalidomide and low-risk MDS patients without 5q- and serum erythropoietin of less than 500 mU/ml are recommended to treat with erythropoietin or darbepoetin alpha. These new agents are currently under clinical trials in Japan.
Ohyashiki
Kazuma
K
First Department of Internal Medicine (Hematology Division), Tokyo Medical University.
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D001565:Benzoates / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000068256:Darbepoetin alfa; D000077588:Deferasirox; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D009369:Neoplasms / Q000150:complications*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
D001565:Benzoates; D006397:Hematinics; D007502:Iron Chelating Agents; D014230:Triazoles; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D013792:Thalidomide; D000077269:Lenalidomide; D000077588:Deferasirox